17,261 trials
Metastatic Breast Cancer
Primary: Clinical Benefit Rate — 72.5; 67.0 Percentage of Participants — p=0.386
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants Who Responded (Platelet Count >=50 Gi/L and >=2x Baseline) to Eltrombopag Treatment in Cycle 2 or Cycle 3 Given Participants Responded in Cycle 1…
Infections, Streptococcal
Primary: Number of Subjects Reporting Grade 3 Symptoms (Solicited and Unsolicited) — 32; 36; 6; 14 subjects
Carcinoma, Hepatocellular
Primary: Percentage of Participants for Each Type of Response — 0; 2.2; 5.8; 54.7 percentage of participants
Neoplasms, Squamous Cell
Primary: Local Disease Control Rate at 2 Years — 21; 7; 15; 7 Participants
Acute Low Back Pain
Primary: Time to Onset of Perceptible Pain Relief — 47 minutes
Anemia, Sickle Cell
Primary: Gardos Channel Activity — -0.0342; 0.0043; 0.1076 mmol/10^13 cells x min — p=0.080
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) — 131.0; 42.0 Days
Nausea · Vomiting
Primary: Complete Response (Percentage of Patients) — 84 percentage of participants
Influenza
Primary: Percentage of Participants With Solicited Local and Systemic Reactions After Vaccination With Fluzone® 2004-2005 Pediatric Formulation. — 54; 47; 50; 44 Percentage of…
Restless Legs Syndrome
Primary: Drug Related Adverse Events-On-Therapy — 29; 14; 5; 5 Number of Events
Rectal Neoplasms
Primary: Feasibility of Pemetrexed Prior to Surgery — 33; 4 participants
Metastatic Breast Cancer
Primary: Tumor Response — 0; 0; 3; 25 participants — p=0.169
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score — 17.3; 17.1; 17.7; -4.2 units on a scale — p=0.073
Eating Disorders
Primary: Weight Gain — 6.2; 1.5 lbs